Drug Price Trends for NDC 85592-0819

Average Pharmacy Cost for 85592-0819

Drug Name	NDC	Price/Unit ($)	Unit	Date
LACTULOSE 10 GM PACKET	85592-0819-01	7.57169	EACH	2026-03-18
LACTULOSE 10 GM PACKET	85592-0819-30	7.57169	EACH	2026-03-18
LACTULOSE 10 GM PACKET	85592-0819-01	7.51170	EACH	2026-02-18
LACTULOSE 10 GM PACKET	85592-0819-30	7.51170	EACH	2026-02-18
LACTULOSE 10 GM PACKET	85592-0819-01	7.41539	EACH	2026-01-21
LACTULOSE 10 GM PACKET	85592-0819-30	7.41539	EACH	2026-01-21
LACTULOSE 10 GM PACKET	85592-0819-01	7.41862	EACH	2025-12-24

Best Wholesale Price for NDC 85592-0819

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 85592-0819

Last updated: February 23, 2026

What is the Drug Identified by NDC 85592-0819?

NDC 85592-0819 corresponds to Myobloc (botulinum toxin type B). It is used for medical indications including cervical dystonia, limb spasticity, and hyperhidrosis. The drug is marketed by Solstice Neurosciences, a subsidiary of US WorldMeds.

Market Overview

Market Size and Segments

• Global Botox Market (including botulinum toxins) was valued at approximately $4.3 billion in 2022.
• Botulinum toxin Type B segment accounted for roughly 20% of this market, estimated at $860 million annually.
• The segment forecast expects compound annual growth rate (CAGR) of 5% from 2023 to 2028.

Key Drivers

• Growing prevalence of neurological conditions (e.g., cervical dystonia, spasticity).
• Increased off-label use for aesthetic procedures.
• Expansion into new indications such as obesity and pain management.
• Competitive pricing pressures from alternative therapies.

Competitive Landscape

• Major competitors include Myobloc (Neurobloc) from Solstice, Myobloc (botulinum toxin type B), and Xeomin (onabotulinumtoxinA).
• Market share is roughly split as follows:

Product	Estimated Market Share	Notes
Xeomin	50%	Approved for multiple indications
Myobloc (NDC 85592-0819)	30%	Mainly approved for dystonia
Botox (onabotulinumtoxinA)	20%	Dominates aesthetic applications

Regulatory Considerations

• FDA approved Myobloc in 2000.
• Continued approval for indications like cervical dystonia, hyperhidrosis, and spasticity.
• No significant recent label changes or new indications approved as of 2023.

Price Analysis and Projections

Historical Pricing

• Average wholesale price (AWP) for a 100-unit vial of Myobloc ranged between $600 and $800 from 2019 to 2022.
• Price adjustments reflect manufacturing costs, competition, and payer negotiations.

Current Pricing Landscape

Parameter	2023 Average Price (per 100 units)	Notes
Wholesale Acquisition Cost (WAC)	$650 - $750	Variability based on volume and payer discounts
Retail Price	$800 - $1,000	After markup, insurance negotiations

Price Projections (Next 5 Years)

Year	Expected Price Range (per 100 units)	Assumptions
2024	$700 - $800	Slight reduction due to increased competition
2025	$680 - $780	Increased market penetration
2026	$660 - $760	Introduction of biosimilar candidates
2027	$640 - $740	Possible price erosion from biosimilar entries
2028	$620 - $720	Price stabilization or further reductions

Factors Impacting Price Trends

• Entry of biosimilars or generics could reduce prices 15-25% within 3-5 years.
• Market expansion into new indications could increase volume, slightly offsetting price declines.
• Value-based payment models and payer pressure may further compress prices.

Regulatory and Market Risks

• Regulatory delays or restrictions on off-label use could depress volume.
• Competitive products with comparable efficacy and lower price could displace Myobloc.
• Supply chain disruptions impacting manufacturing costs or availability.

Summary Table

Aspect	Details
Current Market Size	~$860 million annually
Projected Growth Rate	5% CAGR (2023-2028)
Price Range (2023)	$600 - $1,000 per 100 units
Expected Price Trend	Slight decline over next 5 years
Main Competitors	Xeomin, Botox, biosimilars
Key Drivers	Increasing indications, market expansion

Key Takeaways

• The Myobloc (NDC 85592-0819) market remains competitive with moderate growth.
• Prices are likely to decline gradually due to biosimilar developments.
• Volume growth may partially offset pricing pressures.
• Market dynamics depend heavily on regulatory changes and therapeutic innovation.

FAQs

1. What factors influence Myobloc's pricing?
   Competition, manufacturing costs, payer negotiations, and biosimilar entry influence pricing.

2. How could biosimilars impact the market?
   Biosimilars could reduce prices by 15-25% and divert market share from branded products.

3. What are the main indications for NDC 85592-0819?
   Cervical dystonia, limb spasticity, hyperhidrosis, and off-label neurological uses.

4. What is the growth outlook for the botulinum toxin Type B segment?
   Approximately 5% CAGR through 2028, driven by increased indication adoption.

5. What regulatory risks could affect pricing?
   Labeling restrictions, delays in approval for new indications, or restrictions on off-label use.

---

References

[1] Research and Markets. (2022). Global Botulinum Toxin Market Report.
[2] IQVIA. (2023). U.S. Prescription Drug Market Analysis.
[3] US Food & Drug Administration. (2023). FDA Drug Approvals and Label Changes.